期刊文献+

早期乳腺癌骨保护治疗 被引量:1

Bone protection therapy in early breast cancer
下载PDF
导出
摘要 乳腺癌是全球女性中最常见的恶性肿瘤,也是中国最常见的恶性肿瘤。大多数乳腺癌患者表现为雌激素或孕激素受体阳性。内分泌治疗是激素受体阳性乳腺癌患者的常用治疗方法。而内分泌治疗与骨损失及骨折风险增加相关。目前对乳腺癌内分泌治疗所致的骨丢失尚无令人满意的防治措施,本文旨对激素受体阳性的早期乳腺癌患者治疗过程中骨量减少或骨质疏松的发生机制及目前早期乳腺癌中预防和治疗骨质疏松药物的进展做一综述。 Breast cancer is the most common maliganacy in women worldwide,including China.Most breast cancer patients show positive estrogen or progesterone receptors.Endocrine therapy is a commonly used treatment for hormone receptor-positive breast cancer patients.Endocrine therapy is associated with increased bone loss and increased risk of fractures.At present,there are no satisfactory prevention and treatment measures for bone loss caused by endocrine therapy of breast cancer.This article aims to explore the mechanism of bone loss or osteoporosis during the treatment of hormone receptor positive early breast cancer patients and its prevention and treatment.
作者 盛笑 石晓琦 成金罗 SHENG Xiao;SHI Xiao-qi;CHENG Jin-luo(Changzhou No.2 People s Hospital,Changzhou 213000,Jiangsu,China)
出处 《中华骨质疏松和骨矿盐疾病杂志》 CSCD 北大核心 2020年第3期280-286,共7页 Chinese Journal Of Osteoporosis And Bone Mineral Research
关键词 乳腺癌 内分泌治疗 骨保护 骨质疏松 breast cancer endocrine therapy bone protection osteoporosis
  • 相关文献

参考文献5

二级参考文献50

  • 1余昕航,党雪菲.唑来膦酸预防老年乳腺癌患者阿那曲唑所致骨质疏松的疗效[J].中国老年学杂志,2014,34(11):3162-3163. 被引量:9
  • 2Arimidex,Tamoxifen,Alone or in Combination(ATAC)Trialists',Group,Forbes JF,Cuzick J,et al.Effect of anastrozolc and tamoxi-fen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAG trial[J].Lancet Oncol,2008,9(1):45-53.
  • 3Crivellari D,Sun Z,Coates AS,et al.Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer:the BIG 1-98 trial[J].J Clin Oncol,2008,26(12):1972-1979.
  • 4Kanis JA.Assessment of fracture risk and its application to screen-ing for Postmenopausal osteoporosis.:synopsis of a WHO report.WHO Study Group[J].Osteoporos Int,1994,4(6):368-381.
  • 5Hadji P.Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis[J].Crit Rev Oncol Hematol,2009,69(1):73-82.
  • 6Skerjanec A,Berenson J,Hsu C,et al.The pharmacokinetics and pharmacodynemics of zoledronic acid in cancer patients with vary-ing degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
  • 7Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic ac-id for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.
  • 8Diel IJ,Bergner R Grotz KA.Adverse effects of bisphosphonates:current issues[J]:J Support Oncol,2007,5(10):475-482.
  • 9Gnant M,Mlineritsch B,Schippinger W,et al.Endocrine therapy plus zoledronic acid in premenopausal breast cancer[J].N Engl J Med,2009,360(7):679-691.
  • 10邵怿,丁罡,陈卓慧,经铃,张绣纹.唑来膦酸治疗恶性肿瘤骨转移性疼痛85例的临床观察[J].实用癌症杂志,2008,23(3):291-292. 被引量:6

共引文献32

同被引文献8

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部